公开(公告)号：US11795218B2

公开(公告)日：2023-10-24

申请号：US16795468

申请日：2020-02-19

Applicant: BioNTech AG ,  Ganymed Pharmaceuticals GmbH ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61N5/10 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  A61K39/39558 ,  A61K47/6851 ,  A61N5/10 ,  C07K16/30 ,  G01N33/57484 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  G01N2333/705 ,  G01N2800/52

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US10724103B2

公开(公告)日：2020-07-28

申请号：US15675148

申请日：2017-08-11

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schluter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: C12Q1/686 ,  C12Q1/6886 ,  C07K14/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  G01N33/53

Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

公开(公告)号：US10302647B2

公开(公告)日：2019-05-28

申请号：US14887979

申请日：2016-03-07

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Gerd Helftenbein ,  Dirk Usener ,  Volker Schluter

IPC: C12Q1/686 ,  G01N33/574 ,  C12Q1/6886 ,  G06F19/22

Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

公开(公告)号：US20170072035A1

公开(公告)日：2017-03-16

申请号：US15341528

申请日：2016-11-02

Applicant: BioNTech AG

Inventor： Thorsten Klamp ,  Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Thomas Hiller ,  Jens Schumacher

IPC: A61K39/00 ,  C07K14/47 ,  C12N7/00 ,  C07K14/005

Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Abstract translation: 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫治疗。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者内针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者中的自身蛋白质。

公开(公告)号：US09061007B2

公开(公告)日：2015-06-23

申请号：US13826030

申请日：2013-03-14

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski

IPC: A61K31/21 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/574 ,  A61K31/7088 ,  C12N15/82 ,  A61K47/48

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.

Abstract translation: 本发明涉及有可能评估和/或预测癌症疾病，癌症疾病的转移行为和/或癌症复发的方法。 特别地，本发明的方法使得有可能评估和/或预测癌症转移的发生，特别是远处转移。 优选地，本发明的方法允许区分恶性与良性状况。

公开(公告)号：US20180169236A1

公开(公告)日：2018-06-21

申请号：US15675148

申请日：2017-08-11

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schluter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/28 ,  A61K45/06

Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

公开(公告)号：US20160272711A1

公开(公告)日：2016-09-22

申请号：US14442445

申请日：2013-11-12

Applicant: Biontech AG ,  Ganymed Pharmaceuticals AG ,  TRON-Translationale Onkologie an der Universitatsm edizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Christiane Stadler ,  Julia Holland ,  Hayat Bahr-Mahmud ,  Tim Beissert ,  Laura Plum ,  Fabrice Le Gall ,  Arne Jendretzki ,  Markus Fiedler

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74

Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Abstract translation: 本发明提供含有结合结构域的结合剂，所述结合结构域对于能够结合T细胞的CD3和与肿瘤相关的紧密连接蛋白分子特异性的结合结构域是特异性的，以及使用这些结合剂或其编码的核酸来治疗癌症的方法 。

公开(公告)号：US20160159901A1

公开(公告)日：2016-06-09

申请号：US14904011

申请日：2014-07-30

Applicant: GANYMED PHARMACEUTICALS AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG ,  BIONTECH AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  A61K33/24 ,  A61K31/7064 ,  A61K31/7048 ,  A61N5/10 ,  C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  G01N33/574 ,  A61K31/337 ,  A61K31/5365

CPC classification number: C07K16/28 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/24 ,  A61K39/39558 ,  A61K47/6851 ,  A61K2039/505 ,  A61N5/10 ,  C07K16/30 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/705 ,  G01N2800/52

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

Abstract translation: 本发明提供了诊断或治疗包括靶向CLDN6的癌症干细胞的癌症疾病的方法。 特别地，本发明提供了一种确定癌症干细胞的方法，包括检测表达CLDN6的细胞。此外，本发明提供了治疗或预防癌症的方法，包括通过施用具有以下能力的抗体来抑制和/或消除癌症干细胞： 与CLDN6结合至癌症患者。

公开(公告)号：US09194004B2

公开(公告)日：2015-11-24

申请号：US13864411

申请日：2013-04-17

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Gerd Helftenbein ,  Dirk Usener ,  Volker Schluter

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57492 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G06F19/22

Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.

公开(公告)号：US20150247206A1

公开(公告)日：2015-09-03

申请号：US14712233

申请日：2015-05-14

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski

IPC: C12Q1/68 ,  C07K16/40 ,  C07K16/28 ,  G01N33/574 ,  C12N15/113

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.